drugset / Trial / NCT03056053

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

NCT03056053

Phase 2 Completed 113 enrolled Idorsia Pharmaceuticals Ltd.
NaSingle-groupOpen-labelOther

Summary

The main study objective is to assess the content validity and the psychometric characteristics of the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™).

Timeline

Start
2017-02-15
Primary completion
2017-04-21
Completion
2017-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolpidem Small molecule 5 mg Oral
Subject Zolpidem Small molecule 10 mg Oral

Indications